AX-2026-042713 · GHK-Cu · ERP lot ERP-2601-F9816

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 32 min gradient, 214 nm	98.02	% area	≥ 97.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.98	% area	≤ 3.0	PASS
Largest single impurity	RP-HPLC — GHK-Cu 2:1 complex	0.84	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	401.1024	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	401.1191	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+41.6	ppm	± 15	FAIL
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	3.75	%	≤ 10.0	PASS
Counter-ion	no ionisable counter-ion expected	N/A	—	not applicable	NOT TESTED
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.89	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.50	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	6.69	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 32 min gradient	6.77	min	6.56 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.07	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	56,240	—	≥ 20,000	PASS
Resolution to nearest impurity	vs oxidised His (+16 Da)	2.19	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 32 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 56,240, and skew follows the reported asymmetry factor of 1.07. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.84 % impurity against a 98.02 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHK-Cu — main peak	6.77	4,764,076	98.02	—
2	GHK-Cu 2:1 complex	7.43	40,827	0.84	+277.145
3	oxidised His (+16 Da)	6.51	34,022	0.70	+15.995
4	Gly-His dipeptide (−128 Da)	6.02	12,637	0.26	-128.095
5	apo-GHK (copper-free, −62 Da)	6.26	8,749	0.18	-61.930
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 401.1024 Da, computed from C14H22CuN6O4. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 401.1191 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
1+	402.1097	402.1264	0.0167	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.0	98.02	divergence +0.35 pp vs batch median
Total impurities (% area)	1.00	1.98
Largest single impurity (% area)	0.39	0.84
Water (%)	not stated	3.75
Counter-ion (%)	5.1	N/A
Peptide content (%w/w)	90.8	not determined
Endotoxin (EU/mg)	not stated	0.50
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Domestic warehouse despatch → submitter (2–8 °C, 3 d) → laboratory (courier, cold pack, 5 d) → assay.
Assay date: 07 May 2026
Submitted to the index: 01 Jun 2026
Laboratory: VendorInvestigate, Riga, Latvia
Method basis: 32 min gradient · high-resolution MS
Verification status: PARTIAL

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
How much metal is present. The mobile phase dissociates the complex on-column, so the peptide was measured and the metal was not. A purity figure for a metal-complexed peptide without a separate metal determination is half of a result.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

iso_audit01 Jun 2026

Under a quality system a result field and a specification field are different controlled fields, and conflating them is a document-control observation. It is also one of the easiest things in this whole market to fix.

lot_traceability01 Jun 2026

A retail vial at 98.02 % is worth more evidentially than a selected vial at a higher figure. That is the whole argument for recording provenance at all.

quarter_over_quarter01 Jun 2026

A longitudinal set of retail purchases from one supplier across four quarters is the strongest supplier-level evidence available. Several contributors here are building exactly that.

survivor_lots01 Jun 2026

Even a perfectly blind purchase is a lot somebody chose to test. Provenance fixes one selection problem and leaves the other standing.

Section 7

Related records

Same batch — lot ERP-2601-F9816 n=10

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042707	ERP-2601-F9816	Janoshik	2026-Q2	98.53	4.70	96.3	Buyer-sourced	1	MARGINAL
AX-2026-042708	ERP-2601-F9816	Nordanalyt	2026-Q2	98.88	3.87	91.5	Buyer-sourced	1	MARGINAL
AX-2026-042709	ERP-2601-F9816	PeptideMeter	2026-Q2	98.65	3.99	94.6	Buyer-sourced	1	MARGINAL
AX-2026-042710	ERP-2601-F9816	Nordanalyt	2026-Q2	98.65	4.24	99.6	Buyer-sourced	1	MARGINAL
AX-2026-042711	ERP-2601-F9816	Kestrel	2026-Q2	98.53	3.84	89.7	Laboratory-retained	2	MARGINAL
AX-2026-042712	ERP-2601-F9816	PeptideMeter	2026-Q2	98.48	3.08	100.3	Buyer-sourced	1	MARGINAL
AX-2026-042714	ERP-2601-F9816	Kestrel	2026-Q2	98.93	4.31	106.7	Buyer-sourced	2	MARGINAL
AX-2026-042715	ERP-2601-F9816	Nordanalyt	2026-Q2	98.65	3.91	98.7	Buyer-sourced	1	MARGINAL
AX-2026-042716	ERP-2601-F9816	PeptideMeter	2026-Q2	98.80	4.37	92.0	Laboratory-retained	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHK-Cu records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043160	SSA	SSA-2604-V7731	Janoshik	2026-Q2	98.01	4.02	91.8	Buyer-sourced	0	PASS
AX-2026-043157	SSA	SSA-2604-V7731	Medutest	2026-Q2	99.19	5.14	—	Supplier-supplied	0	PASS
AX-2026-041251	WWB	WWB-2512-B1996	PeptideMeter	2026-Q2	99.43	5.87	—	Buyer-sourced	1	MARGINAL
AX-2026-043249	CPC	CPC-2601-D1258	Kestrel	2026-Q2	99.50	6.96	—	Supplier-supplied	0	PASS
AX-2026-043245	CPC	CPC-2601-D1258	PeptideMeter	2026-Q2	98.10	6.57	95.0	Supplier-supplied	0	PASS
AX-2026-041247	WWB	WWB-2512-B1996	PeptideMeter	2026-Q2	99.23	6.09	88.8	Buyer-sourced	1	MARGINAL
AX-2026-042708	ERP	ERP-2601-F9816	Nordanalyt	2026-Q2	98.88	3.87	91.5	Buyer-sourced	1	MARGINAL
AX-2026-043154	SSA	SSA-2604-V7731	PeptideMeter	2026-Q2	97.82	4.82	101.6	Buyer-sourced	0	PASS

Other recent ERP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042706	Survodutide	ERP-2605-E9865	PeptideMeter	2026-Q3	98.38	5.33	103.5	Buyer-sourced	0	PASS
AX-2026-042704	Tesamorelin	ERP-2604-W9463	Janoshik	2026-Q3	99.02	4.08	—	Buyer-sourced	1	MARGINAL
AX-2026-042705	Survodutide	ERP-2605-E9865	Janoshik	2026-Q3	98.24	5.36	92.3	Buyer-sourced	0	PASS
AX-2026-042708	GHK-Cu	ERP-2601-F9816	Nordanalyt	2026-Q2	98.88	3.87	91.5	Buyer-sourced	1	MARGINAL
AX-2026-042694	Liraglutide	ERP-2601-P8985	Kestrel	2026-Q2	99.25	4.35	107.3	Buyer-sourced	1	MARGINAL
AX-2026-042707	GHK-Cu	ERP-2601-F9816	Janoshik	2026-Q2	98.53	4.70	96.3	Buyer-sourced	1	MARGINAL
AX-2026-042711	GHK-Cu	ERP-2601-F9816	Kestrel	2026-Q2	98.53	3.84	89.7	Laboratory-retained	2	MARGINAL
AX-2026-042722	Tirzepatide	ERP-2512-T9616	Medutest	2026-Q2	99.18	2.07	—	Buyer-sourced	1	MARGINAL